Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Charles River Laboratories International, Inc.

Market Cap 8.78B 7.58B 6.97B 6.56B 12.32B 829B 12.42B 82.55B 32.14B 407B 32.96B 32.26B 1,407B P/E 2026 *
29.7x
P/E 2027 * 19.8x
Enterprise Value 10.6B 9.14B 8.4B 7.91B 14.86B 1T 14.99B 99.59B 38.77B 491B 39.77B 38.92B 1,698B EV / Sales 2026 *
2.75x
EV / Sales 2027 * 2.61x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
1 day-1.94%
1 week-2.63%
Current month+2.35%
1 month+16.74%
3 months+21.10%
6 months-4.42%
Current year-7.48%
1 week 159
Extreme 159
162.9
1 month 127.95
Extreme 127.95
163.3
Current year 127.95
Extreme 127.95
193.7
1 year 124.25
Extreme 124.25
193.7
3 years 87.7
Extreme 87.7
251.8
5 years 87.7
Extreme 87.7
388
10 years 59.83
Extreme 59.829
388
Manager TitleAgeSince
Chief Executive Officer 56 04/05/2026
Director of Finance/CFO 58 05/04/2026
Chief Tech/Sci/R&D Officer 45 11/01/2026
Director TitleAgeSince
Chairman 75 31/12/1999
Director/Board Member 56 04/05/2026
Chairman 69 04/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-1.94%-2.63% - - 8.9B
-0.22%-1.14%-11.88%-13.09% 43.51B
+0.76%+9.42%+303.09%+540.82% 33.29B
-4.74%-6.31%+10.75%-20.99% 29.9B
-0.47%-0.35%+3.38%+31.20% 29.34B
+0.06%+4.36%+13.31%+21.11% 25.42B
-0.02%+10.18% - - 14.36B
-0.98%-1.86%+53.43%+106.06% 13.18B
-0.29%-4.40%+3.13%+1.69% 12.72B
+1.67%+1.35%+105.56%+81.16% 12.08B
Average -0.62%+1.60%+60.10%+93.50% 23.76B
Weighted average by Cap. -0.68%+1.76%+61.93%+103.58%

Financials

2026 *2027 *
Net sales 3.85B 3.32B 3.06B 2.88B 5.4B 364B 5.45B 36.21B 14.1B 178B 14.46B 14.15B 617B 3.92B 3.39B 3.11B 2.93B 5.5B 370B 5.55B 36.88B 14.36B 182B 14.73B 14.41B 629B
Net income 285M 246M 226M 213M 400M 26.91B 403M 2.68B 1.04B 13.21B 1.07B 1.05B 45.69B 417M 360M 331M 311M 585M 39.38B 590M 3.92B 1.53B 19.33B 1.57B 1.53B 66.85B
Net Debt 1.81B 1.56B 1.44B 1.35B 2.54B 171B 2.56B 17.03B 6.63B 83.94B 6.8B 6.66B 290B 1.46B 1.26B 1.16B 1.09B 2.05B 138B 2.07B 13.77B 5.36B 67.85B 5.5B 5.38B 235B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
17/06/26 159.00 -1.94%
16/06/26 162.15 -0.46%
15/06/26 162.90 +0.46%
12/06/26 162.15 +0.43%
11/06/26 161.45 -1.13%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
182.34USD
Average target price
214.60USD
Spread / Average Target
+17.69%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!